Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Neoplasma Vol.62, No.2, p.250-258, 2015 |
||
Title: Clinical significance of microRNA-24 expression in esophageal squamous cell carcinoma | ||
Author: W. DONG, B. LI, Z. WANG, Z. ZHANG, J. WANG | ||
Abstract: microRNA-24 has been reported to participate in tumorgenesis and progression by several signaling pathways in various tumors. However, its potential as a serum diagnostic factor and predictive biomarker for esophageal squamous cell carcinoma (ESCC) has not been studied. In the present study, serum samples were collected from 105 pathologically proven ESCC patients and 30 healthy volunteers. All patients were treated with concurrent chemotherapy and radiotherapy. Real-time polymerase chain reaction was carried out to measure the serum miR-24 expression level in all patients and volunteers. The data were compared among radio-sensitive group (CR+PR, 62 patients), radio-resistant group (SD+PD, 43 patients) and healthy volunteers to elucidate the diagnostic value of serum miR-24 testing for ESCC and the predictive value of miR-24 expression of treatment response. In the result, of the 105 ESCC patients enrolled in the study, 62 patients achieved partial or complete response. The serum miR-24 level in ESCC patients is 4.82 times as high as that in healthy subjects(P<0.01), indicating that serum miR-24 expression could be an excellent diagnostic factor. The mean miR-24 serum levels differ by 2.05 folds between radiosensitive group and radioresistant group, indicating that it may serve as a biomarker for predicting the response of ESCC patient to CRT. Furthermore, the responsiveness of therapy is significantly correlated with Cyfra21-1(P<0.05), serum miR-24 level (P<0.05) and the myelosuppression (P<0.01). In the prsent study, we come to the conclusion that serum miR-24 has the potential to serve as a noninvasive biomarker for both ESCC diagnosis and predicting treatment responses to concurrent chemo-radiation therapy. ESCC patients with lower Cyfra21-1, higher miR-24, and severer myelosupression were much more sensitive to CRT. |
||
Keywords: miR-24 expression, esophageal squamous cell carcinoma, chemo-radiation therapy, radiosensitivity | ||
Published online: 14-Jan-2015 | ||
Year: 2015, Volume: 62, Issue: 2 | Page From: 250, Page To: 258 | |
doi:10.4149/neo_2015_030 |
||
|
download file |
|